Compensation Committee
In connection with the closing of the Merger, Richard A. Heyman, Ph.D., Kim C. Drapkin and Cecil B. Pickett, Ph.D. were appointed to the compensation committee
of the Board, and Richard A. Heyman, Ph.D. was appointed the chair of the compensation committee.
Nominating and Corporate Governance Committee
In connection with the closing of the Merger, Cecil B. Pickett, Ph.D., David Arkowitz and Lynne Zydowsky, Ph.D. were appointed to the nominating and
corporate governance committee of the Board, and Cecil B. Pickett, Ph.D. was appointed the chair of the nominating and corporate governance committee.
Indemnification Agreements
On December 22, 2020,
each of the Companys directors and officers entered into the Companys standard form of Indemnification Agreement, which is attached as Exhibit 10.6 to this Current Report on Form 8-K and
incorporated herein by reference.
Resignation of Executive Officers and Principal Officers
In accordance with the Merger Agreement, on December 22, 2020, effective time of the Merger, Meenu Chhabra resigned as President and Chief Executive
Officer of the Company, Marija Zecevic, Ph.D. resigned as the Companys Chief Operating Officer and Mike Alfieri resigned as the Companys principal accounting officer.
Appointment of Principal Officers
In accordance with the
Merger Agreement and an action of the Board, on December 22, 2020, the Board appointed Richard Peters M.D., Ph.D. as the Companys President and Chief Executive Officer, Paulash Mohsen, as Companys Chief Business Officer and Marie
Epstein, as the Companys Principal Accounting Officer, each effective as of the closing of the Merger and to serve at the discretion of the Board.
There are no family relationships among any of the Companys newly appointed principal officers. None of the Companys newly appointed principal
officers has a direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.
Richard Peters M.D., Ph.D. Dr. Peters biographical information is disclosed in the section above under the heading Appointment of
Directors.
Paulash Mohsen, Chief Business Officer and Principal Financial Officer
Mr. Mohsen has served as Yumanitys Chief Business Officer since May 2015. Prior to joining Yumanity, from 2013 to 2015, he served as Country Manager
in Canada for Cubist Pharmaceuticals, which was acquired by Merck & Co., Inc. Previously, Mr. Mohsen served as Vice President, Strategy and Business Operations for Optimer Pharmaceuticals from 2011 to 2013, which was acquired by
Cubist. Prior to Cubist, Mr. Mohsen held strategic and operational roles of increasing responsibility at Pfizer from 1997 to 2011, including Vice President of Strategy and Vice President, Multi-Channel Management. Mr. Mohsen holds a B.S.
in chemical engineering from Brown University, an M.S. in chemical engineering from the Massachusetts Institute of Technology and an M.B.A. from Harvard Business School.
Marie Epstein, Principal Accounting Officer
Ms. Epstein has served as Yumanitys vice president, finance since July 2018. Prior to Yumanity, Ms. Epstein served as chief accounting officer
of Turbonomic, Inc. from June 2015 to June 2018. Prior to joining Turbonomic, Ms. Epstein was chief financial officer of Plastiq from October 2012 to April 2014. Ms. Epstein holds a B.A. in Psychology from Harvard College and an M.S./MBA
in Accounting from Northeastern Universitys DAmore-McKim School of Business. She has held an active CPA license in Massachusetts for over twenty years.